[1] |
Israeli M, Ben-Gal T, Yaari V, et al. Individualized immune monitoring of cardiac transplant recipients by noninvasive longitudinal cellular immunity tests[J]. Transplantation, 2010, 89(8):968-976.
|
[2] |
Shapiro R. End-stage renal disease in 2010: innovative approaches to improve outcomes in transplantation[J]. Nat Rev Nephrol, 2011, 7(2):68-70.
|
[3] |
Brick C, Atouf O, Benseffaj N, et al. Rejection of kidney graft: mechanism and prevention[J]. Nephrol Ther, 2011, 7(1):18-26.
|
[4] |
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients[J]. Am J Transplant, 2009, 9 Suppl 3:S1-155.
|
[5] |
Wieland E, Olbricht CJ, Süsal C, et al. Biomarkers as a tool for management of immunosuppression in transplant patients[J]. Ther Drug Monit, 2010, 32(5):560-572.
|
[6] |
Budde K, Matz M, Dürr M, et al. Biomarkers of over-immunosuppression[J]. Clin Pharmacol Ther, 2011, 90(2):316-322.
|
[7] |
Sommerer C, Zeier M, Meuer S, et al. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients[J]. Transplantation, 2010, 89(11):1417-1423.
|
[8] |
Sommerer C, Schnitzler P, Meuer S, et al. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older[J]. Ther Drug Monit, 2011, 33(6):694-698.
|
[9] |
Uemura T, Riley TR, Khan A, et al. Immune functional assay for immunosuppressive management in post-transplant malignancy[J]. Clin Transplant, 2011, 25(1):E32-37.
|
[10] |
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies[J]. Ann Intern Med, 2011, 155(8):529-536.
|
[11] |
Zhou T, Xue F, Han LZ, et al. Invasive fungal infection after liver transplantation: risk factors and significance of immune cell function monitoring[J]. J Dig Dis, 2011, 12(6):467-475.
|
[12] |
Cheng JW, Shi YH, Fan J, et al. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2011, 137(10):1445-1453.
|
[13] |
Dong JY, Yin H, Li RD, et al. The relationship between adenosine triphosphate within CD4(+) T lymphocytes and acute rejection after liver transplantation[J]. Clin Transplant, 2011, 25(3):E292-296.
|
[14] |
Mizuno S, Hamada T, Nakatani K, et al. Monitoring peripheral blood CD4+ adenosine triphosphate activity after living donor liver transplantation: impact of combination assays of immune function and CYP3A5 genotype[J]. J Hepatobiliary Pancreat Sci, 2011, 18(2):226-232.
|
[15] |
Fishman JA. Infection in solid-organ transplant recipients[J]. N Engl J Med, 2007, 357(25):2601-2614.
|
[16] |
Husain S, Raza K, Pilewski JM, et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection[J]. Transplantation, 2009, 87(12):1852-1857.
|
[17] |
Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risk of infection and rejection: a meta-analysis using an immune function assay[J]. Transplantation, 2006, 82(5):663-668.
|
[18] |
Xue F, Zhang J, Han L, et al. Immune cell function assay in monitoring of adult liver transplantation recipients with infection[J]. Transplantation,2010, 89(5):620-626.
|